Validation of EQ-5D in patients with cervical cancer in Taiwan

Supportive Care in Cancer

Volumn 18, Issue 10, 2010, Pages 1279-1286

  Lang, Hui Chu ^d   Chuang, Linghsiang ^a   Shun, Shiow Ching ^b   Hsieh, Ching Lin ^b   Lan, Chung Fu ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NONE

Author keywords

Cervix neoplasm; EORTC QLQ C30; EQ 5D; Quality of Life; Taiwan

Indexed keywords

ADULT; AGED; ARTICLE; CONSTRUCT VALIDITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; EUROQOL QUESTIONNAIRE; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; OUTPATIENT; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; TAIWAN; TEST RETEST RELIABILITY; UTERINE CERVIX CANCER; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; OUTPATIENTS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SURVIVAL; TAIWAN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84755161665     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0745-9     Document Type: Article

References (35)

1. Division of Statistics DOH (2005) Statistics of causes of death, health and vital statistical. In: Editor ED (ed) Book of statistics of causes of death, health and vital statistical. Department of Health, Executive Yuan, R. O. C. Taipei
2. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, Weiderpass E (2004) Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 91:935-941
3. Hou SI, Fernandez ME, Baumler E, Parcel GS, Chen PH (2003) Correlates of cervical cancer screening among women in Taiwan. Health Care Women Int 24:384-398
4. Liao CC, Wang HY, Lin RS, Hsieh CY, Sung FC (2006) Addressing Taiwan's high incidence of cervical cancer: factors associated with the Nation's low compliance with Papanicolaou screening in Taiwan. Public Health 120:1170-1176
5. Nayfield SG, Ganz PA, Moinpour CM, Cella DF, Hailey BJ (1992) Report from a National Cancer Institute (USA) workshop on quality of life assessment in cancer clinical trials. Qual Life Res 1:203-210
6. Osoba D (1992) The quality of life committee of the clinical trials group of the national cancer institute of Canada: organization and functions. Qual Life Res 1:211-218
7. Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C (2003) Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol 56:52-60
8. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
9. Gold MR, Patrick DL, Torrance DG (1996) Identifying and valuing outcomes. In: Gold MR (ed) Cost-effectiveness in health and medicine. Oxford University Press, New York, pp 82-134
10. Patrick DL, Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27: S217-S232
11. Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol Group. Ann Med 33:337-343
12. Badia X, Schiaffino A, Alonso J, Herdman M (1998) Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 7:311-322
13. Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736-741
14. Drummond M (2001) Introducing economic and quality of life measurements into clinical studies. Ann Med 33:344-349
15. Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ (2004) Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 13:1247-1253
16. Anderson H, Palmer MK (1998) Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. Br J Cancer 77 (Suppl 2):9-14
17. Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schroder FH (1998) Short-term effects of population based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 90:925-931
18. Polsky D, Keating NL, Weeks JC, Schulman KA (2002) Patient choice of breast cancer treatment: impact on health state preferences. Med Care 40:1068-1079
19. Trippoli S, Vaiani M, Lucioni C, Messori A (2001) Quality of life and utility in patients with non-small cell lung cancer. Quality-oflife study group of the master 2 project in pharmacoeconomics. Pharmacoeconomics 19:855-863
20. van den Hout WB, van der Linden YM, Steenland E, Wiggenraad RG, Kievit J, de Haes H, Leer JW (2003) Single-versus multiplefraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95:222-229
21. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32 (Suppl): S66-S81
22. Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53-72
23. Essink-Bot ML, Stouthard ME, Bonsel GJ (1993) Generalizability of valuations on health states collected with the EuroQolcquestionnaire. Health Econ 2:237-246
24. Kind P (1996) The EuroQol instrument: an index of health-related quality of life. In: Spiker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven Publishers, Philadelphia, pp 191-201
25. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095-1108
26. Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P (1998) Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol 9:549-557
27. Kaasa S, Bjordal K, Aaronson N, Moum T, Wist E, Hagen S, Kvikstad A (1995) The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur J Cancer 31 A: 2260-2263
28. Karnofsky DA, Burchenal JH (1950) Present status of clinical cancer chemotherapy. Am J Med 8:767-788
29. Buccheri G, Ferrigno D, Tamburini M (1996) Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32 A: 1135-1141
30. Mor V, Laliberte L, Morris JN, Wiemann M (1984) The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 53:2002-2007
31. Juniper EF, Gordon HG, Roman J (1996) How to develop and validate a new health-related quality of life instrument. In: Spiker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven Publishers, Philadelphia, pp 49-56
32. Brazier J, Jones N, Kind P (1993) Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 2:169-180
33. Nunnally JC, Bernstein IH (1994) Psychometric theory. McGraw-Hill, NY
34. Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159-174
35. Savoia E, Fantini MP, Pandolfi PP, Dallolio L, Collina N (2006) Assessing the construct validity of the Italian version of the EQ-5D: preliminary results from a cross-sectional study in North Italy. Health Qual Life Outcomes 4:47